Cargando…

An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis

Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ziqi, Hong, Zhinan, Zheng, Yuesheng, Dong, Yongwei, He, Wei, Yuan, Yingjia, Guo, Junbiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662105/
https://www.ncbi.nlm.nih.gov/pubmed/33207859
http://dx.doi.org/10.4081/ejh.2020.3155
_version_ 1783609329527554048
author Li, Ziqi
Hong, Zhinan
Zheng, Yuesheng
Dong, Yongwei
He, Wei
Yuan, Yingjia
Guo, Junbiao
author_facet Li, Ziqi
Hong, Zhinan
Zheng, Yuesheng
Dong, Yongwei
He, Wei
Yuan, Yingjia
Guo, Junbiao
author_sort Li, Ziqi
collection PubMed
description Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention.
format Online
Article
Text
id pubmed-7662105
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-76621052020-11-17 An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis Li, Ziqi Hong, Zhinan Zheng, Yuesheng Dong, Yongwei He, Wei Yuan, Yingjia Guo, Junbiao Eur J Histochem Article Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention. PAGEPress Publications, Pavia, Italy 2020-11-06 /pmc/articles/PMC7662105/ /pubmed/33207859 http://dx.doi.org/10.4081/ejh.2020.3155 Text en ©Copyright: the Author(s) http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Li, Ziqi
Hong, Zhinan
Zheng, Yuesheng
Dong, Yongwei
He, Wei
Yuan, Yingjia
Guo, Junbiao
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_full An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_fullStr An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_full_unstemmed An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_short An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_sort emerging potential therapeutic target for osteoporosis: lncrna h19/mir-29a-3p axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662105/
https://www.ncbi.nlm.nih.gov/pubmed/33207859
http://dx.doi.org/10.4081/ejh.2020.3155
work_keys_str_mv AT liziqi anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT hongzhinan anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT zhengyuesheng anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT dongyongwei anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT hewei anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yuanyingjia anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT guojunbiao anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT liziqi emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT hongzhinan emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT zhengyuesheng emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT dongyongwei emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT hewei emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yuanyingjia emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT guojunbiao emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis